Status:
UNKNOWN
Treatment of HYpertension: Morning Versus Evening
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Rationale: The nocturnal blood pressure mean is an independent and stronger predictor of cardiovascular disease (CVD) risk than either daytime office, awake or 24hour mean blood pressure. In general,...
Eligibility Criteria
Inclusion
- Essential hypertension
- Stable blood pressure on treatment with Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Blocker (ARB) and hydrochlorothiazide
- Age between 18 and 85 years
- WHO performance status 0-1
- Available for a time period of 15 weeks
- Written informed consent
- Dippers: Nocturnal blood pressure fall of 10-20% of daytime values.20
- Non-dippers: -Nocturnal blood pressure fall of \<10% of daytime values
Exclusion
- secondary cause of hypertension
- use of ARB because of intolerability (e.g. dry cough) of ACEI
- nocturnal blood pressure fall of \>20% or rise
- renal insufficiency (GFR\<60 ml/min)
- shift work
- pregnancy or wish to get pregnant
- use of other antihypertensive medication than ACEI, ARB, hydrochlorothiazide or a calcium channel blocker
- use of sleeping medication
Key Trial Info
Start Date :
May 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02214498
Start Date
May 1 2015
End Date
May 1 2017
Last Update
August 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, Netherlands